UBS Reiterates Buy on Cross Country Healthcare (CCRN)

September 15, 2016 8:30 AM EDT
Get Alerts CCRN Hot Sheet
Price: $15.13 +1.89%

Rating Summary:
    4 Buy, 3 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade CCRN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

UBS maintained a Buy rating and $16.00 price target on Cross Country Healthcare (NASDAQ: CCRN) as the company reiterated its 3Q outlook. CCRN's 3Q16 EBITDA margin target of 5.0-5.5% is before estimated $0.9 mln of stockbased comp exp, while the EPS outlook of $0.13-$0.15 includes its impact.

Analyst A.J. Riced commented, "CCRN shares have been volatile recently on concerns around the short term drag of the company's investments (to drive nursing candidate attraction and to continue to build its workforce solutions capabilities). We briefly checked with CCRN. Management reports that investment spending is tracking the company's expectations, albeit the benefits from these initiatives are not likely to be noticeable until Q4. Importantly, having finalized July and August results at this point, management is comfortable reiterating its 3Q EBITDA margin outlook of 5.0-5.5% and EPS outlook of $0.13-$0.15. We are maintaining our estimates and believe that the recent weakness in shares provides an attractive buying opportunity."

For an analyst ratings summary and ratings history on Cross Country Healthcare click here. For more ratings news on Cross Country Healthcare click here.

Shares of Cross Country Healthcare closed at $11.67 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

UBS

Add Your Comment